Tuesday, February 7, 2023


Biotechnology News Magazine

Iantrek Reports: 12-month Clinical Results of a Novel Micro-interventional Bio-stenting Procedure Published in the British Journal of Ophthalmology

Latest Posts

Nectin Therapeutics to Collaborate with Merck on Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and...

NTX1088 is a First-in-Class and highly potent monoclonal antibody directed against PVR (CD155), a transmembrane protein expressed on cancer cells and associated with resistance to PD1 and PDL1 immune checkpoint inhibitors.

TransCure bioServices Offers BioVolume 3D Imaging for Insightful Preclinical Oncology Research

BioVolume reconstructs tumors from 3D, RGB, and thermal imaging. The solution is non-invasive, using a machine learning algorithm to automatically calculate subcutaneous tumor length, height, and width.

CLINUVEL Drug Significantly Reduces UV Skin Damage

“Today’s results build upon the decades of research CLINUVEL has conducted into the use of afamelanotide to protect skin from light, with the first evidence that a single dose of the drug has a photoprotective effect in healthy volunteers. These data add to our regulatory dossier for XP while further developing our specialised healthcare products for wider populations at highest risk of UV-induced damage and skin cancer,” Dr Bilbao said.

Deciphex Completes Validation Activities Enabling Veterinary Consultant Pathologists to Perform CLP Peer Review Digitally Using Patholytix

GLP and non-GLP studies can now be digitally peer reviewed by consultant pathologists for CROs and Pharma companies leading to faster study review and reduced backlogs with Drug candidates brought to clinical trials sooner advises Deciphex.

Iantrek today announced the publication of 12-month clinical results of a novel bio-stenting procedure using the company’s microsurgical instrumentation in the prestigious peer-reviewed journal British Journal of Ophthalmology.

The authorship team, led by glaucoma specialists Drs. Ike Ahmed, Robert Weinreb, and Sean Ianchulev, reports on the long-term outcomes from the use of scleral allograft bio-tissue to stent the supraciliary space and enhance uveoscleral outflow – one of the two major aqueous outflow pathways used in IOP-lowering interventions. The uveoscleral outflow can account for up to 50% of total aqueous outflow in the eye and is the major mechanism of action of first-line therapeutics, such as prostaglandin analogues, for the lowering of IOP.1

In the study, micro-interventional supraciliary stenting achieved a sustained IOP reduction over 12 months – close to 40% reduction from a medicated baseline of 24.2 ± 6.9 mmHg to 14.6 ± 3.2 mmHg (p=0.004). Additionally 80% of the patients achieved more than a 20% reduction in IOP, and the number of glaucoma medications required was reduced 62%.

The bio-stenting approach leverages a highly permeable, conforming scleral allograft bio-tissue delivered using Iantrek’s proprietary micro-surgical instrumentation.

“We are encouraged by the results of this study and the potential of this new approach to improve the lives of millions of people living with glaucoma worldwide,” said Dr. Sean Ianchulev, Founder, Chairman, and CEO of Iantrek, as well as Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai and Director of Ophthalmic Innovation and Technology at the New York Eye and Ear Infirmary of Mount Sinai. “We will continue to invest in research and development to leverage our micro-interventional technologies for ophthalmic surgery.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine